MapLight Therapeutics, Inc.
maplightrx.comWhat Do They Do?
Develops experimental medicines for central nervous system disorders, including schizophrenia, Alzheimer's disease psychosis and autism spectrum disorder.
10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous…View ↗
Our lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a…View ↗
Our second product candidate, ML-004, is a 5-HT1B/1D agonist that we are developing for the treatment of social communication deficit…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$60.2MView ↗
- ▲ +102% (Loss)
- vs −$29.8M in Q2 FY2025
-
Jun 18, 2026
The CFO departed and the chief administrative and accounting officer became interim CFO
Sources
8-K, filed Jun 18, 2026
On June 18, 2026, Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective…View ↗
Who Do They Compete With?
Competes with Bristol Myers Squibb, AbbVie, Neurocrine Biosciences, Neumora Therapeutics, Syremis Therapeutics, Acadia Pharmaceuticals, Otsuka Pharmaceutical, and Johnson & Johnson
10-K for FY2025, filed Mar 26, 2026We are aware of several product and product candidates in clinical development that modulate muscarinic receptors, such as Cobenfy (also…View ↗
Loading...
